Equities

SynAct Pharma AB

SynAct Pharma AB

Actions
  • Price (EUR)0.823
  • Today's Change0.027 / 3.33%
  • Shares traded380.00
  • 1 Year change-40.53%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6210824
Total Receivables, Net121511
Total Inventory------
Prepaid expenses0.26170.25
Other current assets, total0.000.000.00
Total current assets7514035
Property, plant & equipment, net0.662.103.18
Goodwill, net------
Intangibles, net152----
Long term investments0.140.270.27
Note receivable - long term------
Other long term assets0.00--0
Total assets22814338
LIABILITIES
Accounts payable9.674.724.25
Accrued expenses144.919.50
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.581.000.98
Other current liabilities, total1.194.380.65
Total current liabilities251515
Total long term debt0.061.062.11
Total debt0.642.063.09
Deferred income tax18----
Minority interest------
Other liabilities, total8.82----
Total liabilities521618
SHAREHOLDERS EQUITY
Common stock4.453.713.25
Additional paid-in capital647395194
Retained earnings (accumulated deficit)(475)(272)(176)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity17612721
Total liabilities & shareholders' equity22814338
Total common shares outstanding363026
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.